DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02907294 (ClinicalTrials.gov)	March 2016	8/3/2016	Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers	Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers	Huntington Disease	Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo	Palobiofarma SL	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Terminated	18 Years	45 Years	Both	8	Phase 1	Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02907294
(ClinicalTrials.gov)

March 2016

8/3/2016

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers

Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers

Huntington Disease

Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo

Palobiofarma SL

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Terminated

18 Years

45 Years

Both

Phase 1

Spain